Clinical Trials Logo

Stress Disorders, Traumatic clinical trials

View clinical trials related to Stress Disorders, Traumatic.

Filter by:

NCT ID: NCT01595477 Completed - Clinical trials for Posttraumatic Stress Disorder

Mind-Body Skills Groups for the Treatment of War-Related Trauma in Children in Gaza

Start date: March 2012
Phase: N/A
Study type: Interventional

The objective of this study is to determine whether participation in a mind-body skills program by war-traumatized children in Gaza will result in improvement of posttraumatic stress symptoms, depression, and decreased hopelessness compared to a control group.

NCT ID: NCT01595464 Completed - Clinical trials for Posttraumatic Stress Disorder

Mind-Body Skills Groups for the Treatment of War-Related Trauma in Adults in Gaza

Start date: March 2012
Phase: N/A
Study type: Interventional

The objective of this study is to determine whether participation in a mind-body skills program by war-traumatized adults in Gaza will result in improvement of posttraumatic stress symptoms and depression, and will increase posttraumatic growth compared to a control group.

NCT ID: NCT01591694 Completed - Depression Clinical Trials

National Child Traumatic Stress Network (NCTSN) Quality Improvement Initiative Database

Start date: April 2012
Phase:
Study type: Observational

Trauma-informed treatment will improve emotional regulation and behavior.

NCT ID: NCT01589575 Completed - Depression Clinical Trials

Anxiety and Depression in Relatives of Critically Ill Patients: Spouses Versus Other Close Relatives

StressRéa
Start date: September 2012
Phase: N/A
Study type: Observational

The main objective of this study is to compare the rate of reported anxiety / depression (HADS >= 8) among spouses and other family members in ICU patients.

NCT ID: NCT01587118 Completed - Clinical trials for Posttraumatic Stress Disorder

An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder

Start date: June 2012
Phase: Phase 4
Study type: Interventional

This is an open-label pilot study of adjunctive asenapine for the treatment of Posttraumatic Stress Disorder (PTSD) in veterans who have not fully remitted to an adequate trial of standard antidepressant treatment.

NCT ID: NCT01581983 Completed - Depression Clinical Trials

Mindfulness Meditation Format Pilot Study

Start date: April 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess feasibility of an internet and individual format of mindfulness meditation in people with posttraumatic stress disorder (PTSD) and depression symptoms

NCT ID: NCT01576510 Completed - Clinical trials for Posttraumatic Stress Disorder (PTSD)

fMRI Predictors of Treatment Response in Posttraumatic Stress Disorder (PTSD)

Start date: August 2010
Phase: N/A
Study type: Interventional

To employ a fear learning-extinction paradigm with functional magnetic resonance imaging (fMRI) and skin conductance response (SCR) assessments among patients with posttraumatic stress disorder (PTSD) and trauma exposed healthy controls, aiming to a) clarify neural circuits underlying PTSD and b) to probe brain based predictors of symptomatic improvement in response to Prolonged Exposure (PE) treatment, and first line treatment for PTSD.

NCT ID: NCT01574118 Terminated - Clinical trials for Chronic Posttraumatic Stress Disorder

Enhancing Exposure Therapy for Post-traumatic Stress Disorder

Start date: April 2012
Phase: Phase 2
Study type: Interventional

This study is investigating a new brief psychotherapy for post-traumatic stress disorder (PTSD) which, modifies an already proven psychotherapy for PTSD by adding two new components and modifying several others. The goal of the study is to determine whether this experimental treatment outperforms the well-established standard treatment.

NCT ID: NCT01571245 Completed - Clinical trials for Post Traumatic Stress Disorder

Predicting Treatment Response Using Psychophysiologic Reactivity Measures

Start date: April 2012
Phase: N/A
Study type: Observational

Objective psychophysiologic reactivity data may be useful for predicting post-traumatic stress disorder (PTSD) treatment response. Given the variety of PTSD treatments and the lack of a clearly superior treatment, a reliable and valid approach to predicting treatment response is needed. Specific Aims: 1). Evaluate the clinical utility of psychophysiologic reactivity measures to predict overall PTSD symptom response among OEF/OIF/OND (Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn) veterans receiving treatment for PTSD. 2). Evaluate the clinical utility of psychophysiologic reactivity measures to predict psychosocial functioning and health-related quality of life (HRQoL) response among OEF/OIF/OND veterans in treatment for PTSD. Exploratory). Develop psychophysiologic, neuropsychological, and/or self-report models to predict PTSD symptom response to pharmacotherapy, psychotherapy, and combined pharmacotherapy/psychotherapy. The investigators will divide psychophysiologic reactivity predictors into two groups: heart rate variability and attentional bias (eye gaze tracking and modified Stroop). The investigators will collect observational and longitudinal data from a treatment-seeking sample of 50 OEF/OIF/OND veterans with PTSD recruited from the Central Arkansas Veterans Healthcare System (CAVHS) Mental Health Clinics.

NCT ID: NCT01569685 Completed - Depression Clinical Trials

The Treatment of Traumatised Refugees With Sertraline Versus Venlafaxine in Combination With Psychotherapy

PTF3
Start date: April 2012
Phase: Phase 4
Study type: Interventional

Background: The treatment of traumatised refugees is one of the areas within the field of psychiatry with the weakest evidence for the different types of treatment. This is a problem for both patients and doctors as well as for society. The treatment of choice today for Post Traumatic Stress disorder (PTSD) is antidepressants from the subgroup of Selektive Serotonin Reuptake Inhibitors (SSRI), among these the drug Sertraline. The evidence for the use of these drugs as treatment for chronically complex PTSD in traumatised refugees is however very limited and a large part of the group is estimated to be insufficiently treated with this type of medicine. Venlafaxine is an antidepressant from the subgroup of dual action product which means that is works on several pathways in the brain. Among others it influences the area in the brain that is responsible for the enhanced anxiety and hyperarousal experienced by traumatised refugees and which is found to be enlarged among patients suffering from PTSD. All together there is not sufficient evidence to conclude which type of medical and psychological treatment that is most efficient when it comes to the treatment of traumatised refugees. Also there is a lack of studies which examines social functioning and the relation between psychosocial resources and outcome from treatment. Furthermore there is a lack of knowledge of predictors of treatment outcome for the individual patients. This study seeks to produce some of this evidence. Method: This study is expected to include approximately 150 patients randomised into two different groups. The patients are treated with Setraline or Venlafaxine depending on the group the randomised to. Patients in both groups are getting the same version of manual based Cognitive Behavioural Therapy that is specially adapted to this group of patients. The treatment period is 6-7 month. The trial endpoints are PTSD-and depression symptoms and social functioning all measured on internationally validated ratings scales. Furthermore the study will examine the relation between expected outcome of treatment from a range of predictors and the actual treatment results for the individual patient. Results: Altogether this study will bring forward new standards for clinical evaluation and treatment of traumatised refugees and the results are expected to be used in reference programmes/clinical guidelines.